Tristel product comes out on top in New Zealand study

Infection prevention, contamination control and hygiene products manufacturing company Tristel announced on Tuesday that in a randomised, single-blind comparison of disinfectants used in ear, nose and throat clinics conducted by a public health authority in New Zealand, its Wipes System proved to be the equal in terms of microbiological efficacy to disinfectants produced by Dupont and Johnson & Johnson.

The AIM-traded firm said that the study, conducted by the Bay of Plenty District Health Board in Tauranga, concluded that the Wipes System has no capital outlay cost, the lowest running cost, the greatest convenience, and the fastest turnaround time for medical instruments of the three products evaluated.

“We are pleased to see at long last the publication in a peer-reviewed journal of this significant study comparing our Wipes System with competitor products manufactured by two of the world's major infection prevention companies,” said CEO Paul Swinney.

“The results affirm the key advantages of our Wipes over alternative chemistries and disinfection methods.

“This is the twenty-fifth peer-reviewed and published scientific paper featuring Tristel products - a body of evidence of our products' attributes that forms one of our company's key strengths.”

Tristel said worldwide sales in the financial year ending June 2012 were £3.3m and are expected to be £8.7m in the year ending June 2016.

At 1421 BST, shares in Tristel were up 1.26% at 161p.